Search

Search Constraints

You searched for: Author/Creator Guerrera, Maria L.

Search Results

1. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Issue 6 (11th May 2020)

2. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia. (13th March 2021)

3. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. (3rd July 2019)

4. CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. Issue 4 (23rd January 2020)

5. Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia. Issue 4 (7th January 2020)

6. MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. (27th November 2017)

7. Partial response or better at six months is prognostic of superior progression‐free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. (18th November 2020)

8. Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. Issue 3 (21st June 2020)

9. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. (5th September 2018)

10. Venetoclax in Previously Treated Waldenström Macroglobulinemia. Issue 1 (1st January 2022)